Sentinel Oncology Partnering

 

FLT3 Kinase Inhibitor Programme

Internal tandem duplication of the FLT3 gene (FLT3-ITD) is a common recurring mutation in acute myeloid leukaemia (AML) and the presence of FLT3-ITD confers poor prognosis on this large sub-group of AML patients.  The FLT3 programme represents an exciting opportunity for the treatment of cancer and recent data have further enhanced this target in a clinical setting. Highlights of the Sentinel Oncology FLT3 inhibitor programme include the following;

 

• Novel, potent and selective IP featuring drug-like small molecules

• Leads display excellent pharmacokinetic properties consistent with oral dosing

• Leads show high selectivity in cellular assays carrying the ITD mutation

 

PARP1 Inhibitor Programme

 Recent clinical data has validated the use of PARP inhibitors in breast cancer indications and further clinical trials in additional cancers are ongoing. Sentinel Oncology has stron ties with clinical researchers in the field of DNA repari inhibitors and highlights of the PARP inhibitor programme include;

 

• Novel, potent and drug-like small molecules

• Strong IP position in this competitive area

• World-class collaborative network and access to novel tumour models

  

Sentinel Oncology is seeking partners for these programmes  to progress them into pre-clinical development. Our flexible approach to collaboration offers multiple licensing mechanisms. Contact us for more details.

 

In-licensing

Sentinel Oncology is also seeking to in-license programmes at an early stage in the Oncology therapeutic area and would encourage organisations and institutions to contact us with any relevant information for review.